- CEO and co-founder of LentiCure B.V. (2023-...), a 100% subsidiary of Erasmus MC.
- CEO and founder of Ventinova Medical. Between 2013 and 2022 he led Ventinova Medical, a company that develops medical ventilation products. Under his leadership, the company grew and became active in more than 20 countries.
- CEO and founder of Dolphys Medical (2003-2013). A company that developed medical implants and ventilation systems. He later passed on the ventilation activities of this company to Ventinova Medical and discontinued the implant business. More information on Linked-In
"We are in a hurry. People with a rare muscle or brain disease are deteriorating every day. And the treatment costs continue to rise. Together we have to change the healthcare market for these types of (ultra) rare diseases diseases."
About Dirk van Asseldonk
Dirk is known for his ability to bring science and business together and his commitment to find new pathways for corporate financing. He has a clear vision of what he wants to achieve and works practically, but also empathetically. He always looks for solutions to business challenges, in which he attaches great importance to quality, safety, sustainability and the people involved.
"For (ultra) rare diseases, we are facing market failure. The current healthcare market needs a different approach, otherwise medicines will become too expensive and unattainable. LentiCure is committed to transparent, socially responsible prices. If we make more profit than needed to guarantee continuity and new developments, then our sales prices are too high and need to be lowered. We are contineously striving to lower costs of goods, while maintaining high quality. At LentiCure, no one has shares, share options or a profit distribution, to prevent a personal focus that would not align with our social company goal."